Open an account

Biohaven

BHVN · NYSE

$11.81+$0.46 (+4.05%)TodayMarket closed ·
Prev close $11.35

About BHVN

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company is headquartered in New Haven, Connecticut and currently employs 274 full-time employees. The company went IPO on 2022-09-23. The company is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.

Employees
274
Headquarters
New Haven, Connecticut
Listed
Sep 23, 2022
Sector
Health Care
Industry
Biotechnology
Website
biohaven.com

BHVN key statistics

Market cap
1.78B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.08M
Volume
1.53M
Open price
$11.35
High today
$11.85
Low today
$11.07
52 Week high
$18.57
52 Week low
$7.48

Biohaven (BHVN) at a glance

As of Oct 20, 2026, Biohaven (BHVN) shares are priced at $11.81, giving the company a market cap of 1.78B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $11.07 and $11.85. The current price is 6.7% above the day's low and 0.3% below its high.

Volume so far is 1.53M shares, below the average of 2.08M shares a day.

Over the past year Biohaven has ranged from $7.48 to $18.57, and now sits 39% of the way up that range.

Biohaven met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.91 per share against an estimate of -$0.7479.

The average analyst price target is $22.22, 88.2% above the current price, from 11 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

45%of 11 analyst ratings say Buy
  • Buy45.5%
  • Hold45.5%
  • Sell9.1%
Price target · 17 analystsAvg $22.22
Low
$10.10
Now
$11.81
High
$44.10

BHVN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 8.3% on average.

  1. Q3 FY24: reported -$1.70 per share against an estimate of -$1.73
  2. Q4 FY24: reported -$1.85 per share against an estimate of -$1.60
  3. Q1 FY25: reported -$2.17 per share against an estimate of -$1.73
  4. Q2 FY25: reported -$1.94 per share against an estimate of -$1.93
  5. Q3 FY25: reported -$1.64 per share against an estimate of -$1.93
  6. Q4 FY25: reported -$1.21 per share against an estimate of -$1.32
  7. Q1 FY26: reported -$0.88 per share against an estimate of -$0.8446
  8. Q2 FY26: reported -$0.91 per share against an estimate of -$0.7479

BHVN news

  • Vandana Singh

    Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement

  • Press releasePRNewswire

    Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

  • Press releasePRNewswire

    Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

  • Press releasePRNewswire

    Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Vandana Singh

    FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program

  • Vandana Singh

    Why Is Biohaven Stock Soaring Wednesday?

  • Press releasePRNewswire

    Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Similar companies

Companies in the same industry as Biohaven

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.